An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...
The drug dupilumab (Dupixent) effectively clears up airways plugged by mucus during an asthma attack, researchers reported ...
Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...
Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.
Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...
Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...
Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...
Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...
Over the last few months, as Len just mentioned, we have delivered multiple important data readouts, showcasing the strength of our robust pipeline and the potential to drive future growth with ...
Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.
Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...
As third-quarter earnings continue to roll out, Novartis makes headlines with the second biggest acquisition of the year; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback